Insider trade

Officer sold ~$829K of UTHR shares in the open market

Traded Oct 1, 2026 · Filed Oct 2, 2026

~$829K
Reported value · 1,480 sh @ $560.19: 51K
Holds after · shares reported: −6.1%
stock since the trade · S&P 500 +1.4%, $571.38 → $536.40 on Oct 5

Why it stands out

United Therapeutics's & GENERAL COUNSEL sold $829K of United Therapeutics shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 1, 2026
Reporting period: Not applicable
Filed with the SEC: Oct 2, 2026

Officer$500K–$1MPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$829,083

Shares × reported transaction price

Timing vs results

57 days after results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $571.38 on Oct 1, 2026, within 5% of its 52-week high, after an 8% rise over the previous 30 trading days

52-week range $415.34 (Oct 28, 2025) to $596.76 (May 6, 2026), 86% of the way up, from 249 adjusted closes. 30 trading days earlier: $529.14 on Aug 19, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001231589-26-000021
Filed / recorded: Oct 2, 2026, 1:30 AM UTC
Added to OQRO: Oct 6, 2026, 9:34 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: UNITED THERAPEUTICS Corp
Issuer CIK: 1082554
Ticker: UTHR
Reporting person: Paul A Mahon
Relationship: Officer
Officer title: EVP & GENERAL COUNSEL
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 1, 2026
Transaction code: S
Shares / units: 1,480
Price per share: $560.19
Acquired / disposed: Disposed (D)
Shares owned after: 51,112
Ownership form: Direct
Amendment: No

Footnotes from the filing

This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Around the same time

9,500Shares · @ $117.76

yesterday

Derivative exercise or conversion — not an open-market buy.

More Official record

CEO sold ~$269K of United Therapeutics

Scheduled in advanceyesterday

CEO sold ~$486K of United Therapeutics

Scheduled in advanceyesterday